Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -76.75% is in line with its 5-year average of -77.63%, around the middle of its 5-year range (-146.66%–-38.79%).
As of the fiscal period ended Tuesday, June 30, 2026. 17.71% above its 12-month average of -93.27%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -76.75%.
RETURN ON EQUITY (ROE)
-76.75%
RETURN ON EQUITY (ROE) AVG TTM
-93.27%
RETURN ON EQUITY (ROE) AVG 3Y
-83.96%
RETURN ON EQUITY (ROE) AVG 5Y
-77.63%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+17.71%
CURRENT VS 3Y AVG
+8.59%
CURRENT VS 5Y AVG
+1.14%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-82.69%
vs the sector median at left
Kalaris Therapeutics Inc
Market Cap
$58.06M
Return on Equity (ROE)
-76.75%
TTM Avg
-93.27%
3Y Avg
-83.96%
5Y Avg
-77.63%
Market Cap
$60.42M
Return on Equity (ROE)
N/A
TTM Avg
-866.00%
3Y Avg
-422.47%
5Y Avg
-312.54%
Market Cap
$60.02M
Return on Equity (ROE)
N/A
TTM Avg
85.37%
3Y Avg
6.44%
5Y Avg
-23.00%
Market Cap
$59.18M
Return on Equity (ROE)
-30.21%
TTM Avg
-215.14%
3Y Avg
-180.32%
5Y Avg
47.11%
Market Cap
$58.44M
Return on Equity (ROE)
N/A
TTM Avg
-285.38%
3Y Avg
-206.98%
5Y Avg
-151.57%
Market Cap
$58.43M
Return on Equity (ROE)
-82.38%
TTM Avg
-68.06%
3Y Avg
-60.95%
5Y Avg
-49.61%
Market Cap
$58.29M
Return on Equity (ROE)
N/A
TTM Avg
71.44%
3Y Avg
1810.59%
5Y Avg
1190.90%
Market Cap
$62.62M
Return on Equity (ROE)
-136.82%
TTM Avg
-201.41%
3Y Avg
-55.55%
5Y Avg
-39.58%
Market Cap
$57.76M
Return on Equity (ROE)
-58.99%
TTM Avg
-51.19%
3Y Avg
-1.82%
5Y Avg
11.74%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $58.06M | -76.75% | -93.27% | -83.96% | -77.63% |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | N/A | -866.00% | -422.47% | -312.54% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | 85.37% | 6.44% | -23.00% |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | -30.21% | -215.14% | -180.32% | 47.11% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A | -285.38% | -206.98% | -151.57% |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | -82.38% | -68.06% | -60.95% | -49.61% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A | 71.44% | 1810.59% | 1190.90% |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | -136.82% | -201.41% | -55.55% | -39.58% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | -58.99% | -51.19% | -1.82% | 11.74% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -492.89% | -50.27% | -279.07% | -249.48% |
ROE
-76.7%
ROA
-44.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -76.75% |
| 2026-03-31 | -64.32% |
| 2025-12-31 | -55.11% |
| 2025-09-30 | -123.51% |
| 2025-06-30 | -146.66% |
| 2025-03-31 | -113.03% |
| 2024-12-31 | -57.73% |
| 2024-06-30 | -47.22% |
| 2024-03-31 | -80.05% |
| 2023-09-30 | -86.45% |
| 2023-06-30 | -72.74% |
| 2023-03-31 | -85.79% |
| 2022-12-31 | -75.14% |
| 2022-09-30 | -74.45% |
| 2022-06-30 | -121.38% |
| 2022-03-31 | -96.47% |
| 2021-12-31 | -76.34% |
| 2021-09-30 | -52.08% |
| 2021-06-30 | -38.79% |
| 2021-03-31 | -27.66% |
| 2020-12-31 | -19.77% |
| 2020-09-30 | -14.26% |
| 2020-06-30 | -36.32% |
| 2020-03-31 | -27.10% |
| 2019-12-31 | -19.60% |
